• News

"Two Large Trials Investigate Combination Immunotherapy In Bladder Cancer" - Brielle Urciuoli

  • Cure Today
  • New York, NY
  • (July 31, 2018)

With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease. Two clinical trials – Imvigor130 and CheckMate-901 – may soon provide that answer. “The takeaway from the first-line trials in metastatic bladder cancer is the questions that are being asked right now are very practical, straightforward questions, but they are questions that can only be answered in the context of a large, randomized clinical trial,” said Matthew Galsky, MD, professor of medicine, urology, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. “We can speculate about that all we want, but the only way to determine those answers definitively is through prospective clinical trials,” he added.

- Matthew Galsky, MD, Professor, Medicine, Hematology and Medical Oncology, Urology, Icahn School of Medicine at Mount Sinai

Learn more